ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ERYP
CUSIPN/A
WebN/A
PhoneN/A
Debt
Debt-to-Equity Ratio0.01
Current Ratio16.52
Quick Ratio16.50
Price-To-Earnings
Trailing P/E Ratio-3.28
Forward P/E Ratio-3.82
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$11.98 per share
Price / Book0.83
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares17,930,000
Market Cap$183.83 million
Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions
What is Erytech Pharma's stock symbol?
Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."
What price target have analysts set for ERYP?
2 brokers have issued 12-month target prices for Erytech Pharma's stock. Their forecasts range from $43.00 to $43.00. On average, they expect Erytech Pharma's share price to reach $43.00 in the next twelve months. This suggests a possible upside of 332.6% from the stock's current price. View Analyst Price Targets for Erytech Pharma.
What is the consensus analysts' recommendation for Erytech Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma.
Who are some of Erytech Pharma's key competitors?
Some companies that are related to Erytech Pharma include Nightstar Therapeutics (NITE), Unity Biotechnology (UBX), Epizyme (EPZM), Hydropothecary (THCX), CymaBay Therapeutics (CBAY), Fate Therapeutics (FATE), AMAG Pharmaceuticals (AMAG), Advanced Medical Solutions (AMS), Viewray (VRAY), CONSORT Med PLC/S (CSRMY), Mesa Laboratories (MLAB), Dova Pharmaceuticals (DOVA), LeMaitre Vascular (LMAT), Sientra (SIEN) and Insys Therapeutics (INSY).
Who are Erytech Pharma's key executives?
Erytech Pharma's management team includes the folowing people:
- Mr. Gil Beyen BVBA, CEO & Chairman (Age 56)
- Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 39)
- Mr. Eric Soyer Ph.D., CFO & COO (Age 52)
- Dr. Alexander Scheer Ph.D., Chief Scientific Officer (Age 56)
- Naomi Eichenbaum, Director Investor Relations
When did Erytech Pharma IPO?
(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.
Has Erytech Pharma been receiving favorable news coverage?
Press coverage about ERYP stock has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Erytech Pharma earned a coverage optimism score of 0.18 on Accern's scale. They also assigned press coverage about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Erytech Pharma.
How do I buy shares of Erytech Pharma?
Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Erytech Pharma's stock price today?
One share of ERYP stock can currently be purchased for approximately $9.94.
How big of a company is Erytech Pharma?
Erytech Pharma has a market capitalization of $183.83 million. The company earns $-37,890,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.
MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
